Know more now.
Discover a better way to help manage your immunotherapy treatment.
As I continue my battle with
cancer, I have learned that we must
be our own advocates and
work with our doctors as a team.
Discover our BESPOKE study of ctDNA-guided therapy for IO cancer management
Be a part of something truly groundbreaking. Join Natera’s BESPOKE IO study to make a difference for individuals who, like you, are managing their cancer with immunotherapy or immuno-oncology (IO) treatment. The study will examine the use of Signatera and the impact it has on treatment decisions for clinical outcomes in cancer patients being treated through immunotherapy. The study will enroll approximately 1700 patients. Natera and its collaborators will collect data on clinical decisions, benefits, and outcomes from enrolled patients for up to two years.
Visit our Signatera BESPOKE IO study page to learn more about joining the study.
What is Signatera?
- There are signs of cancer still in your body
- Treatment (e.g., immunotherapy, chemotherapy, radiation) is working
- The cancer is likely to come back
How is the Signatera test performed?
A one-time analysis of both blood and tissue determines your unique set of tumor mutations.
The test is custom-built and personalized for you
Signatera detects the presence or absence of cancer each time it is ordered as part of your routine follow-up blood tests.
Understanding your Signatera test results
If you have metastatic cancer, a negative result may mean that your treatment was able to decrease the amount of cancer cells to undetectable levels, meaning the treatment has been effective.